Harmaline ameliorating role against liver cirrhosis via hepatic arginase-I activity modulation | ||
| Biochemistry Letters | ||
| Article 1, Volume 20, Issue 1, 2024 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/blj.2021.54605.1011 | ||
| Authors | ||
| Doha Beltagy1; Khloud Gamal Abdelsalam* 2; Tarek Ali3; mai elkey4 | ||
| 1Assistant professor of biochemistry, Faculty of Science, Damanhour University | ||
| 2Biochemistry Division, Chemistry Department, Faculty of Science, Damanhour University, Egypt. | ||
| 3Prof. of Biochemistry, Faculty of Science. Tanta University | ||
| 4biochemistry, faculty of science , tanta university | ||
| Abstract | ||
| Liver cirrhosis, the 11th most common cause of death, is a severe disease that includes inflammation, oxidative damage, also immune response. Harmaline shows the antioxidant and anti-inflammatory mechanisms that aid in partial protection of hepatic cirrhosis. Objective: This work aimed to evaluate the protection effect of harmaline against liver cirrhosis induced by thioacetamide in mice via arginase-1 enzyme activity modulation. Methods: The study was carried out on forty male mice divided into four groups. Control group (GI), thioacetamide group (GII), harmaline group (GIII), and co-treated group (GIV). By the end of the experiment, arginase-1 activity and liver enzymes were measured in serum and liver tissue. Results: The results showed that combined harmaline administration can cause significant suppression of liver inflammation by increasing ariginase-1 activity to nearly normal values. Inhibition of hepatic stellate cell activation and extracellular matrix deposition were also noticed. Conclusion: Harmaline has protective role against liver cirrhosis induced by thioacetamide in mice. It can be therapeutically used as a safe liver support after further in vivo studies. | ||
| Keywords | ||
| Thioacetamide, Cirrhosis; Harmaline; Arginase; liver | ||
|
Statistics Article View: 269 |
||
